Clinical and Genetic Aspects of Juvenile Onset Pompe Disease

Abstract

Little is known about clinical symptomatology and genetics of juvenile onset Pompe disease (JOPD). The aims of this study were to analyze how these children are diagnosed, what clinical problems they have, and how phenotype is related to genotype. To accomplish this, we analyzed retrospectively data of 34 patients diagnosed after their first and before completion of their 18th birthday. Median age at diagnosis was 3.9 (range 1.1–17) years. Eight patients (23.5%) developed initial symptoms in the first year, 12 (35%) between 1 and 7 years, and 6 (18%) thereafter. Eight (23.5%) had no clinical symptoms at the time of diagnosis. Indications for diagnostics were a positive family history in three (9%), hyperCKemia in eight (23.5%), motor developmental delay in three (9%), and muscle weakness and/or pain in 17 (50%). Rare clinical signs were failure to thrive, recurrent diarrhea, and suspected hepatopathy with glycogen storage. Thirty-two different mutations were identified. Twenty-seven patients (79.5%) carried the milder c.32–13T > G mutation, known to be associated with a broad range of phenotypes. Three out of eight patients manifesting within the first year of life showed generalized muscle weakness, hypertrophic cardiomyopathy, and had to be ventilated during the course of disease, thereby demonstrating clinical overlap with infantile onset Pompe disease.

These findings demonstrate that the phenotype of JOPD is broad and that the differential is not only restricted to neuromuscular disorders. Genotypic analysis was useful to delineate subjects with early onset JOPD from those with IOPD, but overall genotype–phenotype correlation was poor.

Keywords

Pompe disease - glucosidase - phenotype - genotype

Publication History

Received: 30 December 2020

Accepted: 27 July 2021

Article published online:
01 December 2021

• References

• 1 van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008; 372 (9646): 1342-1353
• 2 Hahn A, Schänzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med 2019; 7 (13) 283
• 3 Hahn A, Hennermann JB, Huemer M. et al. Diagnosis and care of infants and children with Pompe disease. Klin Padiatr 2020; 232 (02) 55-61
• 4 Kishnani PS, Corzo D, Nicolino M. et al. Recombinant human acid [α]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68 (02) 99-109
• 5 van der Meijden JC, Kruijshaar ME, Harlaar L, Rizopoulos D, van der Beek NAME, van der Ploeg AT. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. J Inherit Metab Dis 2018; 41 (06) 1205-1214
• 6 van der Ploeg AT, Clemens PR, Corzo D. et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010; 362 (15) 1396-1406
• 7 van Capelle CI, van der Meijden JC, van den Hout JMP. et al. Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet J Rare Dis 2016; 11 (01) 65
• 8 Kroos M, Pomponio RJ, van Vliet L. et al; GAA Database Consortium. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 2008; 29 (06) E13-E26
• 9 Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 2000; 137 (02) 283-285
• 10 Hong X, Sadilek M, Gelb MH. A highly multiplexed biochemical assay for analytes in dried blood spots: application to newborn screening and diagnosis of lysosomal storage disorders and other inborn errors of metabolism. Genet Med 2020; 22 (07) 1262-1268
• 11 Lukacs Z, Nieves Cobos P, Wenninger S. et al. Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology 2016; 87 (03) 295-298
• 12 Ünver O, Hacıfazlıoğlu NE, Karatoprak E. et al. The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: a multicenter study. Neuromuscul Disord 2016; 26 (11) 796-800
• 13 Savarese M, Torella A, Musumeci O. et al. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease. Neuromuscul Disord 2018; 28 (07) 586-591
• 14 Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev 2017; 11: CD011539
• 15 van Gelder CM, Poelman E, Plug I. et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis 2016; 39 (03) 383-390
• 16 Case LE, Bjartmar C, Morgan C. et al. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscul Disord 2015; 25 (04) 321-332
• 17 Desai AK, Walters CK, Cope HL, Kazi ZB, DeArmey SM, Kishnani PS. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: clinical experience with rate escalation. Mol Genet Metab 2018; 123 (02) 92-96
• 18 van der Ploeg AT, Kruijshaar ME, Toscano A. et al; European Pompe Consortium. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol 2017; 24 (06) 768-e31
• 19 Bergsma AJ, In 't Groen SLM, van den Dorpel JJA. et al. A genetic modifier of symptom onset in Pompe disease. EBioMedicine 2019; 43: 553-556
• 20 Kroos MA, Pomponio RJ, Hagemans ML. et al. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology 2007; 68 (02) 110-115
• 21 Wens SC, van Gelder CM, Kruijshaar ME. et al. Phenotypical variation within 22 families with Pompe disease. Orphanet J Rare Dis 2013; 8: 182
• 22 Niño MY, In 't Groen SLM, Bergsma AJ. et al. Extension of the Pompe mutation database by linking disease-associated variants to clinical severity. Hum Mutat 2019; 40: 1954-1967
• 23 Dardis A, Zanin I, Zampieri S. et al. Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents. Nucleic Acids Res 2014; 42 (02) 1291-1302
• 24 Reuser AJJ, van der Ploeg AT, Chien YH. et al; On Behalf Of The Pompe Registry Sites. GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry. Hum Mutat 2019; 40 (11) 2146-2164
• 25 Kishnani PS, Amartino HM, Lindberg C, Miller TM, Wilson A, Keutzer J. Pompe Registry Boards of Advisors. Timing of diagnosis of patients with Pompe disease: data from the Pompe registry. Am J Med Genet A 2013; 161A (10) 2431-2443